↑ トップへ　← 戻る

 Drug（薬物リスト） DrugBank | All Description Patterns

   e.g. "Sirolimus", "アダリムマブ"

A　B　C　D　E　F　G　H　 I 　J　K　L　M　N　O　P　Q　R　S　T　U　V　W　X　Y　Z　other

388 / 12,170 descriptions found* Show info (disease name, etc.) on mouse-over.
 No.   薬物名（臨床試験情報から抽出）   DrugBank   KEGG DRUG *   KEGG GENES *   KEGG PATHWAY   指定難病告示番号 * 
 1   36-482-hyaluronoglucosaminidase ph20 (rhuph20)   Hyaluronidase   D04455, D04456, D06604   -   -   1件:
65 
 2   Abatacept   Abatacept   D03203   2件: CD80, CD86   12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis   24件:
11,
13,
19,
41,
44,
46,
49,
50,
51,
53,
55,
60,
65,
84,
93,
96,
97,
107,
164,
222,
271,
284,
285,
300 
 3   Ada gene transfer   -   -   -   -   1件:
65 
 4   Ada pbsc   -   -   -   -   1件:
65 
 5   Ada umbilical cord blood cells   -   -   -   -   1件:
65 
 6   Adagen   Pegademase   D05384   -   -   1件:
65 
 7   Adenosine   Adenosine   D00045   4件: ADORA1, ADORA2A, ADORA2B, ADORA3   12件: Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   3件:
13,
58,
65 
 8   Administration of drug (interferon-gamma 1-b) subcutaneously   -   -   -   -   1件:
65 
 9   Adverse reactions of gammagard subcutaneously at week 12   -   -   -   -   1件:
65 
 10   Adverse reactions of gammagard subcutaneously at week 24   -   -   -   -   1件:
65 
 11   Adverse reactions of gammagard subcutaneously at week 36   -   -   -   -   1件:
65 
 12   Adverse reactions of gammagard subdermally at week 12   -   -   -   -   1件:
65 
 13   Adverse reactions of gammagard subdermally at week 24   -   -   -   -   1件:
65 
 14   Adverse reactions of gammagard subdermally at week 36   -   -   -   -   1件:
65 
 15   Aldesleukin   Aldesleukin   D00748   3件: IL2RA, IL2RB, IL2RG   14件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Primary immunodeficiency, Th1 and Th2 cell differentiation, Th17 cell differentiation, Transcriptional misregulation in cancer, Viral protein interaction with cytokine and cytokine receptor   3件:
49,
65,
97 
 16   Alefacept   Alefacept   D02800   1件: CD58   2件: Cell adhesion molecules (CAMs), Epstein-Barr virus infection   6件:
37,
60,
65,
164,
284,
285 
 17   Alemtuzumab   Alemtuzumab   D02802   -   -   13件:
13,
15,
19,
20,
46,
51,
60,
63,
65,
85,
96,
164,
284 
 18   Alemtuzumab 0.2 mg   Alemtuzumab   D02802   -   -   2件:
65,
164 
 19   Alemtuzumab 0.3 mg   Alemtuzumab   D02802   -   -   2件:
65,
164 
 20   Allogeneic peripheral blood stem cell   -   -   -   -   1件:
65 
 21   Amlodipine   Amlodipine   D00615, D02914, D07450   4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S   34件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   4件:
51,
65,
67,
298 
 22   Anti-cd45   -   -   -   -   3件:
60,
65,
285 
 23   Anti-thymocyte globulin   -   -   -   -   18件:
11,
13,
14,
36,
40,
41,
42,
45,
46,
49,
51,
60,
62,
65,
164,
283,
284,
285 
 24   Anti-thymocyte globulin (rabbit)   Rabbit   -   -   -   3件:
60,
65,
285 
 25   Antithymocyte globulin   -   -   -   -   3件:
60,
65,
284 
 26   Antithymocyte immunoglobulin (rabbit)   Rabbit   -   -   -   2件:
13,
65 
 27   Aproart   -   -   -   -   1件:
65 
 28   Asp1517   -   -   -   -   1件:
65 
 29   Autologous cd34+ cell transduced with g2scid vector   -   -   -   -   1件:
65 
 30   Autologous cd34+ cells transduced ex-vivo with the pcclchimgp91/vsvg lentiviral vector   -   -   -   -   1件:
65 
 31   Autologous cd34+ cells transduced with a lentiviral vector encoding the wasp cdna   -   -   -   -   1件:
65 
 32   Autologous cd34+ cells transduced with the lentiviral vector containing the human wiskott aldrich sy   -   -   -   -   1件:
65 
 33   Autologous cd34+cells transduced with the w1.6_hwasp_wpre (vsvg) lentiviral vector   -   -   -   -   1件:
65 
 34   Autologous ex vivo gene therapy products based on the efs lv encoding for the human adenosine deaminase (ada) gene (efs-ada lv)   Adenosine   D00045   4件: ADORA1, ADORA2A, ADORA2B, ADORA3   12件: Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   1件:
65 
 35   Azathioprine   Azathioprine   D00238, D03033   -   -   18件:
11,
13,
19,
35,
42,
43,
44,
45,
46,
49,
65,
66,
85,
94,
95,
96,
97,
162 
 36   Azelnidipine   Azelnidipine   D01145   4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S   34件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   1件:
65 
 37   B-lymphocyte stimulator (blys)   -   -   -   -   1件:
65 
 38   Bacteriophage   -   -   -   -   1件:
65 
 39   Basiliximab   Basiliximab   D03058   1件: IL2RA   11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor   6件:
2,
50,
65,
97,
222,
228 
 40   Benznidazole   Benznidazole   D02489   -   -   1件:
65 
 41   Betamethasone   Betamethasone   D00244, D00972, D01357, D01402, D01637, D02032, D02286   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   6件:
2,
46,
65,
90,
96,
235 
 42   Biological sampling   -   -   -   -   1件:
65 
 43   Bivigam   Immune globulin human   -   -   -   1件:
65 
 44   Bms-188667   Abatacept   D03203   2件: CD80, CD86   12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis   6件:
46,
49,
65,
96,
97,
271 
 45   Bpx-501 t cells   -   -   -   -   4件:
65,
284,
285,
326 
 46   Bt090   -   -   -   -   1件:
65 
 47   Bt524   -   -   -   -   1件:
65 
 48   Bt595   -   -   -   -   2件:
63,
65 
 49   Bt681   -   -   -   -   1件:
65 
 50   Busilvex   -   -   -   -   4件:
19,
36,
60,
65 
 51   Busulfan   Busulfan   D00248   -   -   13件:
19,
20,
28,
36,
49,
51,
60,
65,
164,
274,
284,
285,
326 
 52   Busulfan iv   Busulfan   D00248   -   -   1件:
65 
 53   Busulfan, cyclophosphamide, atg, gcsf   Cyclophosphamide   D00287, D07760   -   -   2件:
65,
284 
 54   Busulfan, fludarabine and atg   Fludarabine   D01907, D07966   1件: RRM1   5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism   1件:
65 
 55   Busulfan, fludarabine, atg, tli   Fludarabine   D01907, D07966   1件: RRM1   5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism   2件:
65,
284 
 56   C1 inhibitor   Human c1-esterase inhibitor   -   -   -   1件:
65 
 57   C1 inhibitor concentrate   Human c1-esterase inhibitor   -   -   -   1件:
65 
 58   C1-esterase inhibitor [recombinant] (c1-inh-r)   Human c1-esterase inhibitor   -   -   -   1件:
65 
 59   C1-inh   Human c1-esterase inhibitor   -   -   -   1件:
65 
 60   Calcium   Calcium   -   -   -   24件:
6,
13,
19,
46,
49,
51,
65,
68,
75,
79,
84,
93,
94,
95,
96,
97,
214,
215,
222,
224,
235,
265,
298,
299 
 61   Calcium channel blockers (amlodipine, azelnidipine)   Azelnidipine   D01145   4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S   34件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy (ARVC), Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy (DCM), Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy (HCM), Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway   1件:
65 
 62   Campath   Alemtuzumab   D02802   -   -   4件:
49,
51,
60,
65 
 63   Campath -1h   -   -   -   -   1件:
65 
 64   Campath 1h   Alemtuzumab   D02802   -   -   4件:
60,
65,
164,
285 
 65   Campath, fludarabine, cyclophosphamide   Cyclophosphamide   D00287, D07760   -   -   2件:
65,
284 
 66   Cd3/cd19 neg allogeneic bmt   -   -   -   -   1件:
65 
 67   Cd3/cd19 negative allogeneic hematopoietic stem cells   -   -   -   -   1件:
65 
 68   Cd34 stem cell selection therapy   -   -   -   -   3件:
60,
65,
284 
 69   Cd34+   -   -   -   -   1件:
65 
 70   Cd34+ cells transduced with ada retrovir   -   -   -   -   1件:
65 
 71   Cd34+ hscs transduced with the lentivirus vector, vsv-g pseudotyped cl20-4i-ef1a-h?c-opt   -   -   -   -   1件:
65 
 72   Cd34+cells   -   -   -   -   2件:
65,
285 
 73   Choline   Choline   D07690   -   -   4件:
65,
171,
193,
299 
 74   Cutaquig   Immune globulin human   -   -   -   1件:
65 
 75   Cuvitru   Immune globulin human   -   -   -   1件:
65 
 76   Cuvitru 200 mg/ml solution for subcutaneous injection   Immune globulin human   -   -   -   1件:
65 
 77   Cyclophosphamide   Cyclophosphamide   D00287, D07760   -   -   43件:
13,
14,
16,
19,
20,
26,
28,
35,
36,
40,
41,
42,
43,
44,
45,
46,
49,
50,
51,
52,
56,
60,
61,
62,
65,
66,
84,
85,
93,
96,
162,
164,
172,
222,
224,
265,
274,
283,
284,
285,
288,
326,
331 
 78   Cyclophosphamide 30   Cyclophosphamide   D00287, D07760   -   -   3件:
65,
285,
326 
 79   Cyclophosphamide 40   Cyclophosphamide   D00287, D07760   -   -   3件:
65,
285,
326 
 80   Cyclophosphamide dose level 1   Cyclophosphamide   D00287, D07760   -   -   2件:
65,
284 
 81   Cyclophosphamide dose level 2   Cyclophosphamide   D00287, D07760   -   -   2件:
65,
284 
 82   Cyclophosphamide dose level 3   Cyclophosphamide   D00287, D07760   -   -   2件:
65,
284 
 83   Cyclophosphamide dose level 4   Cyclophosphamide   D00287, D07760   -   -   2件:
65,
284 
 84   Cyclophosphamide post transplant   Cyclophosphamide   D00287, D07760   -   -   1件:
65 
 85   Cyclosporine   Ciclosporin   D00184   5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2   30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway   33件:
11,
14,
19,
20,
28,
36,
40,
41,
42,
45,
46,
49,
50,
53,
56,
58,
60,
62,
64,
65,
90,
95,
97,
162,
164,
222,
226,
228,
234,
283,
284,
285,
302 
 86   Cyclosporins   -   -   -   -   4件:
53,
60,
65,
222 
 87   Daclizumab   Daclizumab   D03639   1件: IL2RA   11件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor   7件:
13,
56,
60,
65,
97,
283,
284 
 88   Danazol   Danazol   D00289   3件: AR, ESR1, PGR   11件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway   4件:
60,
64,
65,
285 
 89   Db289   -   -   -   -   1件:
65 
 90   Depletion in cd45ra graft donor   -   -   -   -   1件:
65 
 91   Dexamethasone   Dexamethasone   D00292, D00975, D01510, D01615, D01632, D01948, D02174, D02591, D02592   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   20件:
13,
16,
28,
35,
46,
53,
63,
65,
70,
74,
75,
81,
83,
84,
90,
96,
97,
222,
296,
299 
 92   Dexamethasone sodium phosphate   Dexamethasone   D00292, D00975, D01510, D01615, D01632, D01948, D02174, D02591, D02592   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   2件:
65,
96 
 93   Dexamethasone sodium phosphate ph. eur.   Dexamethasone   D00292, D00975, D01510, D01615, D01632, D01948, D02174, D02591, D02592   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   1件:
65 
 94   Dextrose, 5% in water   Water   D00001   -   -   1件:
65 
 95   Donor peripheral blood stem cells.   -   -   -   -   1件:
65 
 96   Durvalumab   Durvalumab   D10808   1件: CD274   2件: Cell adhesion molecules (CAMs), PD-L1 expression and PD-1 checkpoint pathway in cancer   1件:
65 
 97   Efficacy of gammagard subcutaneously at week 12   -   -   -   -   1件:
65 
 98   Efficacy of gammagard subcutaneously at week 24   -   -   -   -   1件:
65 
 99   Efficacy of gammagard subcutaneously at week 36   -   -   -   -   1件:
65 
 100   Efficacy of gammagard subdermally at week 12   -   -   -   -   1件:
65 
 101   Efficacy of gammagard subdermally at week 24   -   -   -   -   1件:
65 
 102   Efficacy of gammagard subdermally at week 36   -   -   -   -   1件:
65 
 103   Eflornithine   Eflornithine   D07883   1件: ODC1   3件: Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways   1件:
65 
 104   Eflornithine plus nifurtimox combination therapy   Eflornithine   D07883   1件: ODC1   3件: Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways   1件:
65 
 105   Elapegademase   Elapegademase   D11017   1件: ADA   3件: Metabolic pathways, Primary immunodeficiency, Purine metabolism   1件:
65 
 106   Elapegademase-lvlr   Elapegademase   D11017   1件: ADA   3件: Metabolic pathways, Primary immunodeficiency, Purine metabolism   1件:
65 
 107   Ep2006   -   -   -   -   1件:
65 
 108   Ep2006 (filgrastim)   Filgrastim   D03235   1件: CSF3R   5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer   1件:
65 
 109   Etoposide   Etoposide   D00125, D04107   2件: TOP2A, TOP2B   1件: Platinum drug resistance   11件:
11,
13,
14,
26,
28,
34,
60,
65,
85,
164,
331 
 110   Ezn-2279   -   -   -   -   1件:
65 
 111   Fansidar (pyrimethamine and sulfadoxine)   Pyrimethamine   D00488   -   -   1件:
65 
 112   Fexinidazole   Fexinidazole   D11252   -   -   1件:
65 
 113   Fg-4592/asp1517 - 100 mg   -   -   -   -   1件:
65 
 114   Fg-4592/asp1517 - 20 mg   -   -   -   -   1件:
65 
 115   Fg-4592/asp1517 - 50 mg   -   -   -   -   1件:
65 
 116   Fibrinogen   Fibrinogen human   -   -   -   3件:
14,
65,
288 
 117   Fibrinogen concentrate from human plasma   Fibrinogen human   -   -   -   1件:
65 
 118   Filgrastim   Filgrastim   D03235   1件: CSF3R   5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer   25件:
2,
6,
13,
25,
26,
28,
34,
35,
40,
41,
42,
45,
46,
49,
51,
60,
62,
65,
96,
113,
164,
283,
284,
285,
331 
 119   Filgrastim hexal   Filgrastim   D03235   1件: CSF3R   5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer   1件:
65 
 120   Filgrastim, alemtuzumab   Alemtuzumab   D02802   -   -   1件:
65 
 121   Flebogamma 5% dif   -   -   -   -   1件:
65 
 122   Fludarabina   Fludarabine   D01907, D07966   1件: RRM1   5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism   1件:
65 
 123   Fludarabina teva   Fludarabine   D01907, D07966   1件: RRM1   5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism   1件:
65 
 124   Fludarabine   Fludarabine   D01907, D07966   1件: RRM1   5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism   17件:
13,
28,
36,
46,
49,
51,
60,
61,
62,
65,
85,
96,
164,
283,
284,
285,
326 
 125   Fludarabine monophosphate   Fludarabine   D01907, D07966   1件: RRM1   5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism   4件:
49,
65,
284,
326 
 126   Fludarabine phosphate   Fludarabine   D01907, D07966   1件: RRM1   5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism   11件:
28,
36,
49,
51,
60,
62,
65,
96,
283,
284,
285 
 127   Fludarabine phosphate 30 mg   Fludarabine   D01907, D07966   1件: RRM1   5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism   2件:
65,
164 
 128   Fludarabine phosphate 40 mg   Fludarabine   D01907, D07966   1件: RRM1   5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism   2件:
65,
164 
 129   Fludarabine, busulfan, thymoglobulin   Fludarabine   D01907, D07966   1件: RRM1   5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism   1件:
65 
 130   Fludarabine, melphalan, thiotepa   Fludarabine   D01907, D07966   1件: RRM1   5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism   1件:
65 
 131   Fucose   Fucose   -   -   -   1件:
65 
 132   G-csf   Filgrastim   D03235   1件: CSF3R   5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer   12件:
6,
13,
16,
49,
51,
60,
65,
85,
96,
284,
285,
331 
 133   G-csf for conditioning before hsct.   Filgrastim   D03235   1件: CSF3R   5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer   1件:
65 
 134   G1xcg   -   -   -   -   1件:
65 
 135   G1xcgd transduced cd34+ cells   -   -   -   -   1件:
65 
 136   Gadolinium   Gadolinium   -   -   -   6件:
13,
34,
46,
58,
65,
305 
 137   Gadolinium for abdomen   Gadolinium   -   -   -   1件:
65 
 138   Gadolinium for lower back   Gadolinium   -   -   -   1件:
65 
 139   Gammagard liquid   Immune globulin human   -   -   -   1件:
65 
 140   Gammagard s/d (solvent/detergent)   Immune globulin human   -   -   -   1件:
65 
 141   Gammaglobulin   -   -   -   -   1件:
65 
 142   Gammanorm   -   -   -   -   2件:
14,
65 
 143   Gammanorm 165 mg/ml   -   -   -   -   1件:
65 
 144   Gammaplex   Immune globulin human   -   -   -   1件:
65 
 145   Gammaplex (5%)   -   -   -   -   1件:
65 
 146   Gammaplex (intravenous immunoglobulin)   Immune globulin human   -   -   -   1件:
65 
 147   Gammaplex 10   -   -   -   -   1件:
65 
 148   Gamunex-c   Immune globulin human   -   -   -   1件:
65 
 149   Gcsf   Filgrastim   D03235   1件: CSF3R   5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer   3件:
36,
65,
284 
 150   Gene therapy method for cgd   -   -   -   -   1件:
65 
 151   Gene transfer   -   -   -   -   1件:
65 
 152   Gene-transduced autologous cd34+ stem cells   -   -   -   -   1件:
65 
 153   Genetically modified autologous blood stem cells   -   -   -   -   1件:
65 
 154   Glycolic acid   Glycolic acid   -   -   -   1件:
65 
 155   Glycosade   -   -   -   -   3件:
65,
256,
257 
 156   Gtg003.08   -   -   -   -   1件:
65 
 157   Gvhd prophylaxis   -   -   -   -   2件:
60,
65 
 158   Haemocomplettan p   -   -   -   -   1件:
65 
 159   Haplo bm with t cell depletion   -   -   -   -   1件:
65 
 160   Hematopoetic stem cell transplantation   -   -   -   -   5件:
19,
65,
120,
160,
326 
 161   Hematopoietic stem cell transplant   -   -   -   -   1件:
65 
 162   Hizentra   Immune globulin human   -   -   -   2件:
14,
65 
 163   Hizentra®   Immune globulin human   -   -   -   2件:
14,
65 
 164   Htlp   -   -   -   -   1件:
65 
 165   Human fibrinogen   Fibrinogen human   -   -   -   1件:
65 
 166   Human fibrinogen concentrate   Fibrinogen human   -   -   -   1件:
65 
 167   Human immunglobulin g (igg)   -   -   -   -   1件:
65 
 168   Human normal immunoglobulin   Immune globulin human   -   -   -   8件:
11,
13,
14,
43,
45,
50,
63,
65 
 169   Human normal immunoglobulin (iv)   Immune globulin human   -   -   -   4件:
11,
14,
63,
65 
 170   Human normal immunoglobulin (ivig)   Immune globulin human   -   -   -   2件:
50,
65 
 171   Human normal immunoglobulin (subcutaneous - intramuscular immunoglobulin)   Immune globulin human   -   -   -   1件:
65 
 172   Human normal immunoglobulin for   Immune globulin human   -   -   -   1件:
65 
 173   Human normal immunoglobulin for intravenous administration   Immune globulin human   -   -   -   2件:
14,
65 
 174   Human normal immunoglobulin for intravenous use   Immune globulin human   -   -   -   2件:
63,
65 
 175   Human normal immunoglobulin for intravenous use (ivig)   Immune globulin human   -   -   -   1件:
65 
 176   Human normal immunoglobulin for subcutaneous administration   Immune globulin human   -   -   -   1件:
65 
 177   Human normal immunoglobulin for subcutaneous administration (igsc)   Immune globulin human   -   -   -   1件:
65 
 178   Hyaluronidase   Hyaluronidase   D04455, D04456, D06604   -   -   3件:
28,
65,
331 
 179   Hyaluronoglucosaminidase   Hyaluronidase   D04455, D04456, D06604   -   -   1件:
65 
 180   Hydroxyurea   Hydroxyurea   D00341   1件: RRM2   6件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism, p53 signaling pathway   8件:
3,
13,
19,
20,
65,
85,
86,
284 
 181   Hyqvia   Immune globulin human   -   -   -   2件:
14,
65 
 182   Hyqvia 100 mg/ml solution for infusion for subcutaneous use   Immune globulin human   -   -   -   2件:
14,
65 
 183   I10e   -   -   -   -   3件:
14,
63,
65 
 184   Ibuprofen   Ibuprofen   D00126, D01122, D04490, D06606   2件: PTGS1, PTGS2   21件: Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway   6件:
13,
46,
65,
113,
271,
299 
 185   Ifn-gamma   -   -   -   -   1件:
65 
 186   Ig vena 50 g/l solution for infusion 100 ml vial + infusion set   -   -   -   -   2件:
63,
65 
 187   Igg next generation   -   -   -   -   2件:
63,
65 
 188   Ighy10   -   -   -   -   1件:
65 
 189   Igiv, 10%   -   -   -   -   2件:
14,
65 
 190   Igiv, 10% only   -   -   -   -   1件:
65 
 191   Igiv-c 10%   -   -   -   -   1件:
65 
 192   Ignextgen 16%   -   -   -   -   1件:
65 
 193   Igng   -   -   -   -   1件:
65 
 194   Igpro10   -   -   -   -   3件:
14,
51,
65 
 195   Igpro20   -   -   -   -   3件:
14,
51,
65 
 196   Igsc - rhuph20 then igsc or igiv   -   -   -   -   1件:
65 
 197   Igsc 20%   -   -   -   -   1件:
65 
 198   Igsc 20% 150 mg/kg   -   -   -   -   1件:
65 
 199   Igsc 20% daily push versus 2 times per week pump   -   -   -   -   1件:
65 
 200   Igsc 20% daily push versus every 2 weeks pump   -   -   -   -   1件:
65 
 201   Igsc 20% daily push versus once a week pump   -   -   -   -   1件:
65 
 202   Igsc, 16%   -   -   -   -   1件:
65 
 203   Igsc, 20%   -   -   -   -   1件:
65 
 204   Immune globulin infusion (human), 10%   -   -   -   -   1件:
65 
 205   Immune globulin intravenous   Immune globulin human   -   -   -   3件:
14,
63,
65 
 206   Immune globulin intravenous (human)   Immune globulin human   -   -   -   1件:
65 
 207   Immune globulin intravenous (human) 5% liquid, ivig-sn™   Immune globulin human   -   -   -   1件:
65 
 208   Immune globulin intravenous (human), 10%   Immune globulin human   -   -   -   2件:
14,
65 
 209   Immune globulin intravenous (human), 10% solution   Immune globulin human   -   -   -   1件:
65 
 210   Immune globulin intravenous (human), 10% tvr (triple virally reduced) solution   Immune globulin human   -   -   -   1件:
65 
 211   Immune globulin intravenous [human], 10% caprylate/chromatography purified   Immune globulin human   -   -   -   1件:
65 
 212   Immune globulin subcutaneos, 20%   Immune globulin human   -   -   -   1件:
65 
 213   Immune globulin subcutaneous   Immune globulin human   -   -   -   2件:
14,
65 
 214   Immune globulin subcutaneous (human)   Immune globulin human   -   -   -   2件:
14,
65 
 215   Immune globulin subcutaneous (human) (scig)   Immune globulin human   -   -   -   1件:
65 
 216   Immune globulin subcutaneous (human) igpro20   Immune globulin human   -   -   -   1件:
65 
 217   Immune globulin subcutaneous (human), 20%   Immune globulin human   -   -   -   1件:
65 
 218   Immune globulin subcutaneous (human), 20% caprylate/chromatography purified (igsc 20%)   Immune globulin human   -   -   -   1件:
65 
 219   Immune globulin subcutaneous (human), 20% solution   Immune globulin human   -   -   -   1件:
65 
 220   Immune globulin subcutaneous (human), 20%, caprylate/chromatography purified   Immune globulin human   -   -   -   1件:
65 
 221   Immunoglobulin g   -   -   -   -   7件:
11,
13,
14,
49,
50,
63,
65 
 222   Immunoglobulin g (ig nextgen 16%)   -   -   -   -   1件:
65 
 223   Immunoglobulin intravenous (human)   -   -   -   -   1件:
65 
 224   Immunoglobulins intravenous (human)   -   -   -   -   1件:
65 
 225   Immunological diagnosis tests   -   -   -   -   1件:
65 
 226   Immunosuppression only conditioning (ioc)   -   -   -   -   1件:
65 
 227   Immunosuppression only conditioning - closed with amendment l   -   -   -   -   1件:
65 
 228   Increlex   Mecasermin   D03297, D04870   2件: GHR, IGF1R   33件: AMPK signaling pathway, Adherens junction, Autophagy - animal, Breast cancer, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Focal adhesion, FoxO signaling pathway, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, JAK-STAT signaling pathway, Long-term depression, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Melanoma, Neuroactive ligand-receptor interaction, Oocyte meiosis, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Signaling pathways regulating pluripotency of stem cells, Transcriptional misregulation in cancer, mTOR signaling pathway   3件:
65,
78,
96 
 229   Infliximab   Infliximab   D02598   1件: TNF   61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway   22件:
35,
37,
38,
39,
40,
41,
43,
45,
46,
49,
50,
56,
65,
84,
95,
96,
97,
98,
162,
164,
269,
271 
 230   Interferon gamma   -   -   -   -   2件:
65,
326 
 231   Interferon gamma-1b   -   -   -   -   7件:
65,
85,
90,
228,
299,
301,
326 
 232   Interferon-gamma   -   -   -   -   1件:
65 
 233   Interleukin-2   Human interleukin-2   -   -   -   6件:
2,
35,
49,
55,
65,
97 
 234   Intratect   -   -   -   -   3件:
13,
35,
65 
 235   Intravenous immunoglobulin   Immune globulin human   -   -   -   16件:
2,
11,
14,
17,
18,
35,
38,
39,
49,
51,
63,
65,
85,
164,
296,
309 
 236   Intravenous infusion of transduced cells   -   -   -   -   1件:
65 
 237   Itraconazole   Itraconazole   D00350   -   -   4件:
3,
65,
227,
299 
 238   Ivig   Immune globulin human   -   -   -   12件:
11,
13,
14,
17,
18,
50,
51,
63,
65,
85,
164,
296 
 239   Kedrion ivig 10%   Immune globulin human   -   -   -   1件:
65 
 240   Kineret   Anakinra   D02934   2件: IL1R1, IL1R2   15件: Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer   5件:
41,
49,
65,
266,
299 
 241   Kiovig   Immune globulin human   -   -   -   2件:
14,
65 
 242   Kiovig 100 mg/ml solution for infusion   Immune globulin human   -   -   -   2件:
14,
65 
 243   L-fucose   Fucose   -   -   -   1件:
65 
 244   Ladicell   -   -   -   -   1件:
65 
 245   Lemtrada   Alemtuzumab   D02802   -   -   2件:
13,
65 
 246   Lenograstim   Lenograstim   D03247   1件: CSF3R   5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer   3件:
2,
57,
65 
 247   Lentiviral g1xcgd gene therapy   -   -   -   -   1件:
65 
 248   Lentiviral vector transduced cd34+ cells   -   -   -   -   1件:
65 
 249   Lfb-igsc   -   -   -   -   1件:
65 
 250   Mabthera   -   -   -   -   15件:
11,
13,
35,
46,
50,
51,
53,
61,
63,
64,
65,
83,
162,
222,
271 
 251   Mavorixafor   -   -   -   -   1件:
65 
 252   Mctls   -   -   -   -   1件:
65 
 253   Medi1123   -   -   -   -   1件:
65 
 254   Medi4736   -   -   -   -   1件:
65 
 255   Melarsoprol   Melarsoprol   D00832   -   -   1件:
65 
 256   Melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d   Eflornithine   D07883   1件: ODC1   3件: Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways   1件:
65 
 257   Melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d   Melarsoprol   D00832   -   -   1件:
65 
 258   Melphalan   Melphalan   D00369   -   -   14件:
11,
13,
14,
19,
20,
28,
60,
62,
65,
96,
164,
234,
284,
285 
 259   Mesna   Coenzyme m   -   -   -   9件:
13,
44,
45,
49,
51,
60,
65,
96,
164 
 260   Methotrexate   Methotrexate   D00142, D02115   2件: DHFR, DHFR2   4件: Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate   33件:
11,
13,
19,
34,
35,
41,
42,
43,
44,
45,
46,
49,
50,
51,
53,
55,
56,
60,
62,
65,
84,
93,
96,
97,
162,
164,
172,
256,
271,
284,
285,
326,
331 
 261   Methylprednisolone   Methylprednisolone   D00407, D00751, D00979, D05000, D05001, D05002   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   36件:
2,
13,
25,
26,
35,
38,
39,
40,
41,
42,
43,
45,
46,
49,
50,
51,
60,
63,
64,
65,
66,
83,
84,
86,
96,
97,
145,
164,
220,
222,
224,
271,
283,
284,
285,
296 
 262   Methylprednisolone or prednisolone   Methylprednisolone   D00407, D00751, D00979, D05000, D05001, D05002   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   1件:
65 
 263   Mozobil 20mg/ml vial (injectable solution for subcutaneous use)   Plerixafor   D08971   1件: CXCR4   12件: Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral protein interaction with cytokine and cytokine receptor   1件:
65 
 264   Mozobil 20mg/ml vial (injectable solution, subcutaneous use)   Plerixafor   D08971   1件: CXCR4   12件: Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral protein interaction with cytokine and cytokine receptor   1件:
65 
 265   Mycophenolate   Mycophenolic acid   D05096   2件: IMPDH1, IMPDH2   3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism   33件:
2,
11,
13,
14,
19,
20,
28,
35,
36,
42,
43,
45,
49,
51,
53,
60,
62,
65,
66,
84,
85,
95,
96,
162,
164,
222,
224,
226,
234,
283,
284,
285,
300 
 266   Mycophenolate mofetil   Mycophenolate mofetil   D00752, D05094, D05095   2件: IMPDH1, IMPDH2   3件: Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism   32件:
2,
11,
13,
14,
19,
20,
28,
35,
36,
42,
43,
45,
49,
51,
53,
60,
62,
65,
66,
85,
95,
96,
162,
164,
222,
224,
226,
234,
283,
284,
285,
300 
 267   Myeloablative conditioning-closed with amendment l   -   -   -   -   1件:
65 
 268   Myeloablative preparative regimen   -   -   -   -   3件:
62,
65,
284 
 269   Myelostim 34 milions ui/ml - powder and solvent for solution for injection/infusion   -   -   -   -   1件:
65 
 270   Myelostim 34 milions ui/ml, powder and solvent for solution for injection or infusion   -   -   -   -   1件:
65 
 271   Nanogam 100 mg/ml   -   -   -   -   1件:
65 
 272   Nanogam® 50 mg/ml   -   -   -   -   1件:
65 
 273   Neopterin   Neopterin   -   -   -   1件:
65 
 274   Newgam   -   -   -   -   3件:
14,
63,
65 
 275   Nifurtimox   Nifurtimox   D00833   -   -   1件:
65 
 276   Nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d   Eflornithine   D07883   1件: ODC1   3件: Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways   1件:
65 
 277   Nifurtimox-eflronithine combination treatment (nect)   Nifurtimox   D00833   -   -   1件:
65 
 278   Noxafil 40 mg/ml oral solution   -   -   -   -   1件:
65 
 279   Octagam 10%   -   -   -   -   3件:
50,
63,
65 
 280   Octagam 5%   -   -   -   -   2件:
13,
65 
 281   Octagam 50 mg/ml oldatos infúzió   -   -   -   -   1件:
65 
 282   Octanorm   -   -   -   -   2件:
50,
65 
 283   Octanorm 16.5%   -   -   -   -   2件:
50,
65 
 284   Omalizumab   Omalizumab   D05251   1件: FCER1A   4件: Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway   6件:
53,
65,
98,
162,
226,
299 
 285   Omalizumab (xolair)   Omalizumab   D05251   1件: FCER1A   4件: Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway   1件:
65 
 286   Orencia   Abatacept   D03203   2件: CD80, CD86   12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis   9件:
46,
50,
51,
53,
65,
84,
96,
97,
271 
 287   Orencia® 125 mg solution for injection in pre-filled syringe   Abatacept   D03203   2件: CD80, CD86   12件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis   1件:
65 
 288   Otl-101   -   -   -   -   1件:
65 
 289   Ovastat   Treosulfan   D07253   -   -   2件:
13,
65 
 290   Ovastat 1000 (treosulfan injection)   Treosulfan   D07253   -   -   1件:
65 
 291   Ovastat 5000 (treosulfan injection)   Treosulfan   D07253   -   -   1件:
65 
 292   Palifermin   Palifermin   D05338   1件: FGFR2   12件: Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells   4件:
13,
38,
39,
65 
 293   Pantoprazole   Pantoprazole   D02593, D05353   2件: ATP4A, ATP4B   4件: Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation   2件:
13,
65 
 294   Pantoprazolo 20 mg gastro-resistant tablets   -   -   -   -   1件:
65 
 295   Peg-interleukin-2   Human interleukin-2   -   -   -   1件:
65 
 296   Pentamidine   Pentamidine   D00834, D08333   -   -   1件:
65 
 297   Phagocyte oxidase subunit transduced cd34 hematopoietic stem cells   -   -   -   -   1件:
65 
 298   Phosphate   Phosphate ion   -   -   -   29件:
2,
3,
11,
12,
13,
28,
36,
46,
49,
51,
53,
60,
62,
65,
70,
78,
81,
83,
90,
96,
97,
164,
235,
256,
283,
284,
285,
286,
299 
 299   Pioglitazone   Pioglitazone   D00945, D08378   1件: PPARG   9件: AMPK signaling pathway, Huntington disease, Longevity regulating pathway, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer   17件:
2,
6,
13,
15,
20,
46,
49,
65,
67,
78,
81,
86,
96,
229,
265,
298,
299 
 300   Plerixafor   Plerixafor   D08971   1件: CXCR4   12件: Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral protein interaction with cytokine and cytokine receptor   4件:
51,
65,
285,
299 
 301   Plerixafor for conditioning before hsct.   Plerixafor   D08971   1件: CXCR4   12件: Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral protein interaction with cytokine and cytokine receptor   1件:
65 
 302   Pneumo 23   -   -   -   -   1件:
65 
 303   Polyclonal igg   -   -   -   -   1件:
65 
 304   Posaconazole   Posaconazole   D02555   -   -   3件:
60,
65,
299 
 305   Posaconazole (psz)   Posaconazole   D02555   -   -   1件:
65 
 306   Prednisolone   Prednisolone   D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   38件:
11,
13,
25,
26,
35,
38,
39,
41,
43,
44,
45,
46,
49,
50,
51,
56,
60,
61,
63,
64,
65,
66,
75,
81,
84,
85,
95,
96,
97,
113,
145,
162,
222,
269,
271,
296,
299,
300 
 307   Prednisone   Prednisone   D00473   1件: NR3C1   1件: Neuroactive ligand-receptor interaction   43件:
2,
11,
13,
14,
26,
35,
40,
41,
42,
43,
44,
45,
46,
49,
50,
51,
53,
61,
63,
64,
65,
66,
81,
84,
85,
86,
95,
96,
97,
113,
162,
164,
222,
224,
228,
251,
283,
284,
285,
288,
299,
300,
331 
 308   Prevenar   -   -   -   -   1件:
65 
 309   Privigen   Immune globulin human   -   -   -   4件:
11,
14,
51,
65 
 310   Proleukin® s   Aldesleukin   D00748   3件: IL2RA, IL2RB, IL2RG   14件: Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Inflammatory bowel disease (IBD), JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Primary immunodeficiency, Th1 and Th2 cell differentiation, Th17 cell differentiation, Transcriptional misregulation in cancer, Viral protein interaction with cytokine and cytokine receptor   1件:
65 
 311   Promacta   Eltrombopag   D03978   -   -   1件:
65 
 312   Psrs11.efs.il2rg.pre* retroviral vector   -   -   -   -   1件:
65 
 313   Psrs11.efs.il2rg.pre* retroviral vector transduce   -   -   -   -   1件:
65 
 314   Psrs11.efs.il2rg.pre* retroviral vector transduced cells   -   -   -   -   1件:
65 
 315   Pth 1-34   Teriparatide   D06078   1件: PTH1R   3件: Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action   2件:
65,
235 
 316   Pyrimethamine   Pyrimethamine   D00488   -   -   4件:
2,
4,
19,
65 
 317   Rabbit   Rabbit   -   -   -   7件:
13,
49,
51,
60,
65,
96,
285 
 318   Rabbit anti-thymocyte globulin   Rabbit   -   -   -   2件:
49,
65 
 319   Ranitidine   Ranitidine   D00422, D00673   1件: HRH2   3件: Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction   2件:
13,
65 
 320   Recombinant human hyaluronidase   Hyaluronidase   D04455, D04456, D06604   -   -   2件:
28,
65 
 321   Recombinant human hyaluronidase (rhuph20)   Hyaluronidase   D04455, D04456, D06604   -   -   1件:
65 
 322   Recombinant human hyaluronidase (rhuph20)+ immune globulin intravenous (igiv)   Hyaluronidase   D04455, D04456, D06604   -   -   1件:
65 
 323   Recombinant human hyaluronidase + immune globulin intravenous   Hyaluronidase   D04455, D04456, D06604   -   -   1件:
65 
 324   Reduced intensity conditioning   -   -   -   -   2件:
19,
65 
 325   Reduced intensity conditioning (ric)   -   -   -   -   1件:
65 
 326   Reduced intensity preparative regimen   -   -   -   -   3件:
62,
65,
284 
 327   Reduced toxicity ablative regimen   -   -   -   -   3件:
62,
65,
284 
 328   Retroviral sf71-gp91phox transduced cd34+ cells   -   -   -   -   1件:
65 
 329   Retrovirus-mediated gene transfer   -   -   -   -   1件:
65 
 330   Rhucd40l   -   -   -   -   1件:
65 
 331   Ri-002   -   -   -   -   1件:
65 
 332   Rimiducid   -   -   -   -   5件:
19,
65,
284,
285,
326 
 333   Rituximab   Rituximab   D02994   1件: MS4A1   1件: Hematopoietic cell lineage   42件:
11,
13,
14,
17,
35,
36,
43,
44,
45,
46,
49,
50,
51,
52,
53,
56,
60,
61,
63,
64,
65,
66,
83,
84,
85,
86,
93,
94,
96,
97,
162,
222,
223,
229,
256,
271,
283,
284,
285,
288,
300,
331 
 334   Rituximab (rtx) and azathioprine (aza)   Azathioprine   D00238, D03033   -   -   1件:
65 
 335   Rivogenlecleucel   -   -   -   -   4件:
19,
65,
284,
285 
 336   Roxadustat   Roxadustat   D10593   3件: EGLN1, EGLN2, EGLN3   3件: HIF-1 signaling pathway, Pathways in cancer, Renal cell carcinoma   1件:
65 
 337   Rp-l201   -   -   -   -   1件:
65 
 338   Scid screening   -   -   -   -   1件:
65 
 339   Scyx 7158   -   -   -   -   1件:
65 
 340   Scyx-7158   -   -   -   -   1件:
65 
 341   Sirolimus   Sirolimus   D00753   1件: MTOR   43件: AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Choline metabolism in cancer, Colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway   30件:
13,
17,
34,
35,
36,
46,
51,
60,
62,
63,
65,
66,
67,
85,
89,
96,
98,
137,
157,
158,
192,
222,
277,
278,
279,
280,
281,
283,
285,
331 
 342   Somatic gene-therapy by x-cgd   -   -   -   -   1件:
65 
 343   Sta-5326   -   -   -   -   2件:
65,
96 
 344   Stelara (ustekinumab)   Ustekinumab   D09214   3件: IL12A, IL12B, IL23A   25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus   1件:
65 
 345   Stem cell transplant   -   -   -   -   2件:
60,
65 
 346   Stem cell transplantation   -   -   -   -   9件:
13,
19,
20,
46,
65,
90,
164,
234,
326 
 347   Strimvelis   -   -   -   -   1件:
65 
 348   Subcuvia   -   -   -   -   3件:
14,
49,
65 
 349   Subgam   -   -   -   -   1件:
65 
 350   Sulfadoxine   Sulfadoxine   D00580   -   -   1件:
65 
 351   Suspension of autologous cd34+cells transduced with the g1xcgd viral vector   -   -   -   -   1件:
65 
 352   T-cell depleted & cd34+select/w/stemcell enriched product   -   -   -   -   1件:
65 
 353   Tabelecleucel   -   -   -   -   1件:
65 
 354   Tablets fexinidazole   Fexinidazole   D11252   -   -   1件:
65 
 355   Tacrolimus   Tacrolimus   D00107, D08556   5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2   30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway   29件:
2,
11,
13,
36,
46,
49,
50,
51,
53,
60,
61,
62,
65,
66,
85,
95,
96,
97,
113,
151,
158,
164,
222,
224,
226,
228,
283,
284,
299 
 356   Tadekinig alfa   Tadekinig alfa   -   -   -   1件:
65 
 357   Tbx-1400   -   -   -   -   1件:
65 
 358   Tcr alfa beta t cell depletion   -   -   -   -   1件:
65 
 359   Thalidomide   Thalidomide   D00754   1件: TNF   61件: AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis (ALS), Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Dilated cardiomyopathy (DCM), Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy (HCM), IL-17 signaling pathway, Inflammatory bowel disease (IBD), Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway   18件:
2,
16,
20,
28,
49,
51,
53,
65,
84,
85,
94,
96,
97,
227,
271,
280,
298,
331 
 360   Therapeutic allogeneic lymphocytes   -   -   -   -   2件:
60,
65 
 361   Thiotepa   Thiotepa   D00583   -   -   11件:
13,
19,
20,
28,
51,
60,
65,
85,
96,
164,
284 
 362   Thiotepa--escalated dose   Thiotepa   D00583   -   -   4件:
19,
20,
65,
284 
 363   Thiotepa--single daily dose   Thiotepa   D00583   -   -   4件:
19,
20,
65,
284 
 364   Thymoglobuline   -   -   -   -   4件:
13,
36,
51,
65 
 365   Thymus tissue for transplantation   -   -   -   -   1件:
65 
 366   Thymus/parathyroid transplantation   -   -   -   -   2件:
65,
235 
 367   Traditional treatment of cgd and tb   -   -   -   -   1件:
65 
 368   Transduced lymphocytes   -   -   -   -   1件:
65 
 369   Transplant conditioning with mobilization and alemtuzumab   Alemtuzumab   D02802   -   -   1件:
65 
 370   Transplant conditioning with mobilization only   -   -   -   -   1件:
65 
 371   Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan   Alemtuzumab, Fludarabine   D01907, D02802, D07966   1件: RRM1   5件: Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism   2件:
65,
164 
 372   Tremelimumab   Tremelimumab   D06657   1件: CTLA4   4件: Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Rheumatoid arthritis, T cell receptor signaling pathway   1件:
65 
 373   Treosulfan   Treosulfan   D07253   -   -   3件:
13,
19,
65 
 374   Tyf-il-2rg gene-modified autologous stem cells   -   -   -   -   1件:
65 
 375   Unrelated bm with t cell depletion   -   -   -   -   1件:
65 
 376   Unrelated cord blood   -   -   -   -   1件:
65 
 377   Ustekinumab   Ustekinumab   D09214   3件: IL12A, IL12B, IL23A   25件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease (IBD), Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus   15件:
37,
41,
46,
49,
50,
53,
56,
65,
84,
93,
96,
97,
162,
269,
271 
 378   Valacyclovir   Valaciclovir   D00398, D08664, D10518   -   -   1件:
65 
 379   Valproic acid   Valproic acid   D00399   7件: ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2   17件: Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism   10件:
3,
5,
26,
34,
65,
89,
90,
222,
256,
331 
 380   Verorab® (pvrv   -   -   -   -   1件:
65 
 381   Vigantol   -   -   -   -   2件:
13,
65 
 382   Vitamin d3   Cholecalciferol   D00188   1件: VDR   4件: Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis   11件:
6,
13,
20,
46,
49,
53,
60,
65,
96,
97,
299 
 383   Vivaglobin   Immune globulin human   -   -   -   2件:
14,
65 
 384   Vm106   -   -   -   -   1件:
65 
 385   Water   Water   D00001   -   -   18件:
2,
5,
6,
13,
17,
19,
35,
46,
53,
57,
63,
65,
67,
84,
97,
226,
278,
299 
 386   X4p-001   -   -   -   -   1件:
65 
 387   Xifaxan   Rifaximin   D02554   -   -   2件:
65,
94 
 388   Zoledronate   Zoledronic acid   D01968, D06378, D06379, D08689   1件: FDPS   4件: Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis   2件:
46,
65 

先頭へ